ABI-5366 shows long-acting antiviral activity in models of HSV infection
July 19, 2023
Researchers from Assembly Biosciences Inc. reported on the preclinical characterization of ABI-5366, a potent helicase-primase inhibitor against both HSV-1 and HSV-2.